Literature DB >> 17894012

Subclinical atherosclerosis in primary antiphospholipid syndrome.

Annamaria Margarita1, Joana Batuca, Giovanna Scenna, Jose' Delgado Alves, Louis Lopez, Luigi Iannaccone, Eiji Matsuura, Paul R J Ames.   

Abstract

To test the atherosclerosis hypothesis in primary antiphospholipid syndrome (PAPS) we measured intima media thickness (IMT) of carotid arteries and other cardiovascular risk factors in 44 patients with PAPS (mean age 35 +/- 12 years), in 25 patients with inherited thrombophilia (mean age 40 +/- 10 years), and in 34 normal controls (mean age 38 +/- 11 years). The frequency of smoking, hypertension, and dyslipidemia was similar across groups. IMT was almost similar across groups at age groups below 40 years but IMT was greater in PAPS than controls at the common carotid (P = 0.01), at the bifurcation (P = 0.003), and at the internal carotid (P = 0.005) in the age group over 40 years. Atherosclerosis is a possibility in PAPS patients in their fourth decade of life or older.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17894012     DOI: 10.1196/annals.1422.050

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome.

Authors:  Robert C Grenn; Srilakshmi Yalavarthi; Alex A Gandhi; Nayef M Kazzaz; Carlos Núñez-Álvarez; Diego Hernández-Ramírez; Antonio R Cabral; W Joseph McCune; Paula L Bockenstedt; Jason S Knight
Journal:  Ann Rheum Dis       Date:  2016-07-18       Impact factor: 19.103

2.  Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.

Authors:  Darcy S Majka; Kiang Liu; Richard M Pope; Elizabeth W Karlson; Thanh-Huyen T Vu; Marius Teodorescu; Rowland W Chang
Journal:  Inflamm Res       Date:  2013-10       Impact factor: 4.575

Review 3.  Is preclinical autoimmunity benign?: The case of cardiovascular disease.

Authors:  Darcy S Majka; Rowland W Chang
Journal:  Rheum Dis Clin North Am       Date:  2014-09-17       Impact factor: 2.670

Review 4.  Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome.

Authors:  Roberta Gualtierotti; Martina Biggioggero; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 5.  Atherosclerosis in autoimmune diseases.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Luis R Lopez
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 6.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 7.  Cardiovascular risk factors in the antiphospholipid syndrome.

Authors:  Felipe Freire da Silva; Roger Abramino Levy; Jozélio Freire de Carvalho
Journal:  J Immunol Res       Date:  2014-07-13       Impact factor: 4.818

8.  Antiphospholipid (Hughes) syndrome: beyond pregnancy morbidity and thrombosis.

Authors:  Maria Mialdea; Shirish R Sangle; David P D'Cruz
Journal:  J Autoimmune Dis       Date:  2009-05-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.